User profiles for F.M. Marty

Francisco Marty

Brigham and Women's Hospital – Dana-Farber Cancer Institute
Verified email at partners.org
Cited by 20147

Role of (1→ 3)-β-D-glucan in the diagnosis of invasive aspergillosis

FM Marty, S Koo - Medical mycology, 2009 - Taylor & Francis
Measurement of serum (1→3)-β-D-Glucan (BG) is an aid in the diagnosis of fungemia and
deep-seated mycoses, including invasive aspergillosis (IA). BG is present in the cell wall of …

Early remdesivir to prevent progression to severe Covid-19 in outpatients

…, N Behenna-Renton, F Duff, FM Marty… - … England Journal of …, 2022 - Mass Medical Soc
Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe
coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

Infectious complications associated with immunomodulating biologic agents

S Koo, FM Marty, LR Baden - Hematology/Oncology Clinics, 2011 - hemonc.theclinics.com
The repertoire of monoclonal antibodies and other biologic therapies targeted at precise
components of the immune response continues to expand rapidly. In theory, these therapies …

Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation

…, SP Hammond, H Einsele, FM Marty - Blood …, 2018 - ashpublications.org
Patients treated with allogeneic hematopoietic cell transplantation (HCT) are at risk of
cytomegalovirus (CMV) reactivation and disease, which results in increased morbidity and mortality…

Remdesivir for 5 or 10 days in patients with severe Covid-19

…, J Muñoz, KM Mullane, FM Marty… - … England Journal of …, 2020 - Mass Medical Soc
Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …

[HTML][HTML] Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial

…, S Bhagani, MY Ahn, AJ Sanyal, G Huhn, FM Marty… - Jama, 2020 - jamanetwork.com
Importance Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients
with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate …

[HTML][HTML] Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation

FM Marty, P Ljungman, RF Chemaly… - … England Journal of …, 2017 - Mass Medical Soc
Background Cytomegalovirus (CMV) infection remains a common complication after allogeneic
hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV–…

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

FM Marty, L Ostrosky-Zeichner, OA Cornely… - The Lancet infectious …, 2016 - thelancet.com
Background Mucormycosis is an uncommon invasive fungal disease with high mortality and
few treatment options. Isavuconazole is a triazole active in vitro and in animal models …

[HTML][HTML] Transmission of lymphocytic choriomeningitis virus by organ transplantation

…, CN Kotton, A Srinivasan, FM Marty… - … England Journal of …, 2006 - Mass Medical Soc
Background In December 2003 and April 2005, signs and symptoms suggestive of infection
developed in two groups of recipients of solid-organ transplants. Each cluster was …

Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants

FM Marty, LA Cosimi, LR Baden - New England Journal of …, 2004 - Mass Medical Soc
To the Editor: The Food and Drug Administration (FDA) approved voriconazole for the treatment
of invasive aspergillosis partly on the basis of data published in a report in the Journal, 1 …